engine Protein Arrays
Your chance for breaking discoveries
Our high-density protein arrays present over 15,000 human proteins and peptides derived from different tissues. The corresponding cDNA expression libraries were validated, and advanced in more than 15 years of experience. The combination of established, published and well-characterized antigens and neoantigens enables you to discover novel biomarkers hypothesis-free and unbiased.
Unique coverage of human proteome
High content of >15,000 full-length antigens, protein isoforms & peptides, neoantigens & frameshift peptides.
Largest neoantigen library
Frameshift mutations are commonly the cause of severe pathologies. Investigate, if neoantigens and frameshift peptides are relevant in your disease of interest.
Robust & documented technology
hEXselect Protein Array
Human fetal brain cDNA library
>57,000 spots in total with >21,000 distinct human antigens representing >7,000 different genes.
1,100 € per array, bulk discount possible
UniPEx Protein Array
Human fetal brain, T-cells, lung and colon cDNA library
>36,000 spots in total with >15,000 distinct human antigens representing >6,000 different genes.
1,100 € per array, bulk discount possible
Custom Protein Array
Generated from subsets of our human fetal brain, T-cells, lung and colon cDNA library. Size ranges from 500 up to 13,000. Clones spotted in duplicates.
Prices on request.
Investigate if citrullination, phosphorylation or carbamylation are disease-associated or causative. Our protein arrays can be modified enzymatically. For example, rheumatoid arthritis autoantibodies are usually directed against cyclic citrullinated peptides.
Protein array research database
What our customers say
“To identify potential biomarkers associated with axial spondyloarthritis, we used the engine biomarker screening service. As a first step, we had the autoantibody profiles of 4 patients investigated. In the course of this investigation on UniPEx arrays, more than 50 potential antigens could be identified. A subarray was created for these candidates and in a second step, a larger number of patients could easily be testet. This allowed us, to further narrow down our potential biomarker candidates. These will now be validated in further studies on a different platform. The engine protein arrays are a great tool for broad biomarker screening in the field of autoimmune diseases. The engine team has supported us throughout the process and the screening service has allowed us to focus on our other projects in parallel with the testing.”
Torsten Witte, ProF. Dr. med.
Director of the Clinic for Rheumatology and Immunology, Hannover Medical School
“We screened B-cell receptors of central nervous system lymphoma with UniPEx arrays and discovered potential biomarkers, which we have successfully validated with antigens expressed in eukaryontic cells. With the prompt assistance of the engine team, we were able to continue our validation experiments in an uncomplicated manner and look forward to presenting the results in a paper soon.”
Technical assistant at Jose Carreras Centre for Immunology and Gene Therapy at Saarland University Hospital
“We used the protein macroarrays to screen for protein-protein interaction (PPI) partners using fluorophore-labelled peptide baits. This enabled us to identify the histone lysine N-methyltransferase EHMT2/G9a as an interaction partner and functional modulator of trans-activation domains of transcription factors of the C/EBP family (1). We have further extended these PPI screens on UniPEx Arrays and to differentially post-translationally modified (PTM) peptides as baits. Thereby, we could not only measure large numbers of protein interactions on approximately one-third of the proteome simultaneously, but also explore a protein´s interactome depending on defined PTM states (2). An advantage of this approach using UniPEx protein/peptide libraries was the presence of large amounts of unmodified pray protein (expressed in E. coli) in combination with a defined duplicate spotting pattern, which enables quick exclusion of false-positive interactions.”
Ole Pless, PhD
Fraunhofer IME Screening Port, Hamburg, Germany
“We used the hEXselect multiprotein-array to identify interaction partners of antisera directed to bacteria, which are suspected to cause schizophrenia in the offspring of mothers infected during early pregnancy. ( 1, 2) By this we could identify a handful of interesting candidate molecules which have later been functionally characterized. In the course of these experiments, the hEXselect multiprotein-array turned out to be a highly valuable tool that is comparably easy to handle, making the experimental procedures nearly as simple as a western blot! However, even more important for our project was the fact, that the cDNAs in the expression library used for this array, were derived from the frontal cortex of two human fetal brains of the late first and the early second trimester of pregnancy, thereby covering in terms of schizophrenia pathology almost perfectly the expression pattern during the most vulnerable phase of prenatal brain development.”
Bernhard Reuss, PhD
Professor for Cellular Neuroanatomy, University Medical Center Göttingen
“To our experience, the protein arrays are super-informative and yield highly reproducible results specifically for biomarker discovery and validation. We have screened Testis, Fetal hEX1, UniPEx and hEXselect protein arrays to identify autologous antibodies specific to Small Cell Lung Cancer (SCLC), Non-small Cell Lung Cancer (NSLCL), Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Behcet’s disease and Neuromyelitis optica (NMO) in comparison with healthy controls. We were able to identify disease specific autologous antibodies and validate them via custom-made arrays. The nature and format of the protein arrays provided us the opportunity to develop a screening protocol by which we were able to generate signals in a broad dynamic range, obtain high signal/background and positive signal/negative signal ratios. Further, we could identify novel autologous antibodies which we will publish after validation with ELISA and Western blot.”